Ralph A. DeFronzo

51.6k total citations · 24 hit papers
284 papers, 38.6k citations indexed

About

Ralph A. DeFronzo is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Ralph A. DeFronzo has authored 284 papers receiving a total of 38.6k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Endocrinology, Diabetes and Metabolism, 133 papers in Molecular Biology and 86 papers in Surgery. Recurrent topics in Ralph A. DeFronzo's work include Metabolism, Diabetes, and Cancer (114 papers), Diabetes Treatment and Management (110 papers) and Pancreatic function and diabetes (73 papers). Ralph A. DeFronzo is often cited by papers focused on Metabolism, Diabetes, and Cancer (114 papers), Diabetes Treatment and Management (110 papers) and Pancreatic function and diabetes (73 papers). Ralph A. DeFronzo collaborates with scholars based in United States, Italy and Qatar. Ralph A. DeFronzo's co-authors include Masafumi Matsuda, Eleuterio Ferrannini, Muhammad Abdul‐Ghani, Lawrence J. Mandarino, Gerald I. Shulman, Muhammad Abdul-Ghani, Donald C. Simonson, Douglas J. Smith, Robert R. Henry and Edward J. Barrett and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Ralph A. DeFronzo

281 papers receiving 37.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

1999 4.7k citations Ralph A. DeFronzo et al. Diabetes Care profile →
Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

1991 3.7k citations Ralph A. DeFronzo et al. Diabetes Care profile →
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM

1988 2.0k citations Ralph A. DeFronzo Diabetes profile →
Impaired Fasting Glucose and Impaired Glucose Tolerance

2007 1.1k citations Ralph A. DeFronzo, Richard E. Pratley et al. Diabetes Care profile →
Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with Non-Insulin-Dependent Diabetes by¹³C Nuclear Magnetic Resonance Spectroscopy

1990 988 citations Ralph A. DeFronzo et al. profile →
Pathogenesis of type 2 diabetes mellitus

2004 950 citations Ralph A. DeFronzo profile →
Effect of fatty acids on glucose production and utilization in man.

1983 888 citations Ralph A. DeFronzo et al. profile →
The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.

1975 870 citations Ralph A. DeFronzo et al. profile →
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.

1987 683 citations Ralph A. DeFronzo et al. profile →
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.

1989 665 citations Ralph A. DeFronzo et al. profile →
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

2010 648 citations Ralph A. DeFronzo Diabetologia profile →
Glucose Toxicity

1990 644 citations Ralph A. DeFronzo et al. Diabetes Care profile →
The effect of insulin on renal sodium metabolism

1981 536 citations Ralph A. DeFronzo Diabetologia profile →
Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance

2008 535 citations Ralph A. DeFronzo et al. Diabetes profile →
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

2011 523 citations Ralph A. DeFronzo, Devjit Tripathy et al. profile →
Insulin resistance in uremia.

1981 458 citations Ralph A. DeFronzo et al. profile →
Metformin-associated lactic acidosis: Current perspectives on causes and risk

2015 445 citations Ralph A. DeFronzo et al. profile →
Epinephrine-induced Insulin Resistance in Man

1980 439 citations Ralph A. DeFronzo et al. profile →
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary

2020 411 citations Yehuda Handelsman, George Grunberger et al. profile →
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary

2018 377 citations Lawrence Blonde, Ralph A. DeFronzo et al. profile →
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary

2017 327 citations Lawrence Blonde, Ralph A. DeFronzo et al. profile →
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents

2019 315 citations Ralph A. DeFronzo et al. profile →
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary

2019 225 citations Lawrence Blonde, Ralph A. DeFronzo et al. profile →
Insulin: The master regulator of glucose metabolism

2022 184 citations Luke Norton, Chris E. Shannon et al. profile →

Peers

Countries citing papers authored by Ralph A. DeFronzo

Since Specialization

Citations

This map shows the geographic impact of Ralph A. DeFronzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph A. DeFronzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph A. DeFronzo more than expected).

Fields of papers citing papers by Ralph A. DeFronzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph A. DeFronzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph A. DeFronzo. The network helps show where Ralph A. DeFronzo may publish in the future.

Co-authorship network of co-authors of Ralph A. DeFronzo

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph A. DeFronzo. A scholar is included among the top collaborators of Ralph A. DeFronzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph A. DeFronzo. Ralph A. DeFronzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients 2024 ·Diabetes Obesity and Metabolism ·Eugênio Cersósimo, (unknown), (unknown), Alberto O. Chávez, (unknown), (unknown), Curtis Triplitt, Ralph A. DeFronzo	2
2	Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines 2024 ·BMC Medicine ·Stanley S. Schwartz, Barbara E. Corkey, James R. Gavin, Ralph A. DeFronzo, Mary E. Herman	2
3	Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone 2024 ·BMJ Open ·Ralph A. DeFronzo, Richard J. Auchus, Irina Bancos, Lawrence Blonde, Robert S. Busch, John B. Buse, James W. Findling, Vivian Fonseca, Juan P. Frías, Oksana Hamidi, Yehuda Handelsman, Richard E. Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas Moraitis, Daniel Einhorn	0
4	Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects 2024 ·BMJ Open Diabetes Research & Care ·Aurora Merovci, (unknown), (unknown), (unknown), Muhammad Abdul‐Ghani, Eugênio Cersósimo, Curtis Triplitt, Ralph A. DeFronzo	11
5	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases 2023 ·Journal of Diabetes and its Complications ·Yehuda Handelsman, Javed Butler, George L. Bakris, Ralph A. DeFronzo, Gregg C. Fonarow, Jennifer B. Green, George Grunberger, James L. Januzzi, Samuel Klein, Pamela Kushner, Darren K. McGuire, Erin D. Michos, Javier Morales, Richard E. Pratley, Matthew R. Weir, Eugene E. Wright, Vivian Fonseca	43
6	The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals 2023 ·Diabetes Obesity and Metabolism ·(unknown), Ahmed Khattab, John M. Adams, (unknown), Curtis Triplitt, Ralph A. DeFronzo, Muhammad Abdul‐Ghani	1
7	Effects of Sustained Hyperglycemia on Skeletal Muscle Lipids in Healthy Subjects 2022 ·The Journal of Clinical Endocrinology & Metabolism ·Chris E. Shannon, Aurora Merovci, Marcel Fourcaudot, Devjit Tripathy, Muhammad Abdul‐Ghani, Hu Wang, Xianlin Han, Luke Norton, Ralph A. DeFronzo	3
8	Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control 2021 ·Journal of Diabetes Investigation ·Georgios Ponirakis, Muhammad Abdul‐Ghani, Amin Jayyousi, Mahmoud Zirie, (unknown), Hamad Almuhannadi, Ioannis N. Petropoulos, Adnan Khan, Hoda Gad, (unknown), (unknown), (unknown), (unknown), (unknown), Ziyad Mahfoud, Hanadi Al Hamad, Marwan Ramadan, Ralph A. DeFronzo, Rayaz A. Malik	21
9	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children 2020 ·PLoS ONE ·Juan Carlos López-Alvarenga, Geetha Chittoor, Solomon F.D. Paul, Sobha Puppala, Vidya S. Farook, Sharon P. Fowler, Roy G. Resendez, Joselín Hernández-Ruiz, Álvaro Díaz-Badillo, (unknown), (unknown), Donna M. Lehman, Srinivas Mummidi, Rector Arya, Christopher P. Jenkinson, Jane Lynch, Ralph A. DeFronzo, John Blangero, Daniel E. Hale, Ravindranath Duggirala	8
10	Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin 2015 ·Diabetes Care ·Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl	244
11	Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance 2012 ·Diabetes ·Mustafa Kanat, Andrea Mari, Luke Norton, (unknown), Ralph A. DeFronzo, Chris Jenkinson, Muhammad Abdul-Ghani	97
12	Fat-Specific DsbA-L Overexpression Promotes Adiponectin Multimerization and Protects Mice From Diet-Induced Obesity and Insulin Resistance 2012 ·Diabetes ·Meilian Liu, RuiHua Xiang, (unknown), Ning Zhang, Lauren Sloane, (unknown), Lijun Zhou, Hongzhi Chen, Guangda Xiang, Christi A. Walter, Steven N. Austad, Nicolas Musi, Ralph A. DeFronzo, Reto Asmis, Philipp E. Scherer, Lily Dong, Feng Liu	63
13	Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects 2011 ·The Journal of Clinical Endocrinology & Metabolism ·Eugênio Cersósimo, Amalia Gastaldelli, Áurea Cervera, Estela Wajcberg, (unknown), (unknown), Peng Zuo, (unknown), Curtis Triplitt, Nicolas Musi, Ralph A. DeFronzo	43
14	Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention 2011 ·Diabetes Care ·Ralph A. DeFronzo, Muhammad Abdul‐Ghani	112
15	Whole body overexpression of PGC-1α has opposite effects on hepatic and muscle insulin sensitivity 2009 ·American Journal of Physiology-Endocrinology and Metabolism ·Huiyun Liang, Bogdan Balas, Puntip Tantiwong, John J. Dubé, Bret H. Goodpaster, Robert M. O’Doherty, Ralph A. DeFronzo, Arlan Richardson, Nicolas Musi, Walter F. Ward	73
16	Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes 2004 ·Diabetologia ·Ralph A. DeFronzo, Robert E. Ratner, Ji‐Young Han, (unknown), Mark Fineman	2
17	Effects of exercise and insulin on insulin signaling proteins in human skeletal muscle 1999 ·Medicine & Science in Sports & Exercise ·(unknown), Katsumi Maezono, Mary‐Elizabeth Patti, Merri Pendergrass, Ralph A. DeFronzo, Lawrence J. Mandarino	41
18	Current therapy of diabetes mellitus 1998 ·Mosby eBooks ·Ralph A. DeFronzo	37
19	Neonatal de-afferentation of capsaicin-sensitive sensory nerves increases in vivo insulin sensitivity in conscious adult rats 1998 ·Diabetologia ·S.J. Koopmans, Brendan Leighton, Ralph A. DeFronzo	38
20	Non-insulin-dependent diabetes mellitus and gestational diabetes mellitus: Same disease, another name? 1995 ·M. Pendergrass, (unknown), Ralph A. DeFronzo	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact